In a report published Friday, Jefferies reiterated its Buy rating on Biomed Realty Trust BMR, and slightly raised its price target from $23.00 to $24.00.
Jefferies noted, “BMR continues to benefit from a healthy life science environment, with a strong pace of FDA drug approvals and strong capital flows into the industry. As a result, the company has seen strong earnings growth driven by strong leasing and tenant demand. Significant growth opportunities remain through acquisitions, developments, and continued lease-up. Maintain Buy.”
Biomed Realty Trust closed on Thursday at $20.79.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
---|
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in